EGFR trans-activation mediates pleiotrophin-induced activation of Akt and Erk in cultured osteoblasts

Biochemical and Biophysical Research Communications

Volumn 447, Issue 3, 2014, Pages 425-430

  Fan, Jian bo ^a   Liu, Wei ^a   Yuan, Kun ^a   Zhu, Xin hui ^a   Xu, Da wei ^a   Chen, Jia jia ^a   Cui, Zhi ming ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Akt Erk signalings; ALP; Dex; EGF; EGFR; HB EGF; Osteoblasts and bone growth; Pleiotrophin; Ptn

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALKALINE PHOSPHATASE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PLEIOTROPHIN; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; BONE GROWTH; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; MOUSE; MUTATION; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSACTIVATION;

AKT/ERK SIGNALINGS; EGFR; OSTEOBLASTS AND BONE GROWTH; PLEIOTROPHIN;

3T3 CELLS; ANIMALS; CARRIER PROTEINS; CYTOKINES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MICE; OSTEOBLASTS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84900308736     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.04.002     Document Type: Article

References (36)

1. Deuel T.F., Zhang N., Yeh H.J., Silos-Santiago I., Wang Z.Y. Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch. Biochem. Biophys. 2002, 397:162-171.
2. Merenmies J., Rauvala H. Molecular cloning of the 18-kDa growth-associated protein of developing brain. J. Biol. Chem. 1990, 265:16721-16724.
3. Hampton B.S., Marshak D.R., Burgess W.H. Structural and functional characterization of full-length heparin-binding growth associated molecule. Mol. Biol. Cell 1992, 3:85-93.
4. Li G., Bunn J.R., Mushipe M.T., He Q., Chen X. Effects of pleiotrophin (PTN) over-expression on mouse long bone development, fracture healing and bone repair. Calcif. Tissue Int. 2005, 76:299-306.
5. Tare R.S., Oreffo R.O., Clarke N.M., Roach H.I. Pleiotrophin/osteoblast-stimulating factor 1: dissecting its diverse functions in bone formation. J. Bone Miner. Res. 2002, 17:2009-2020.
6. Meng K., Rodriguez-Pena A., Dimitrov T., Chen W., Yamin M., Noda M., Deuel T.F. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:2603-2608.
7. Imai S., Kaksonen M., Raulo E., Kinnunen T., Fages C., Meng X., Lakso M., Rauvala H. Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM). J. Cell Biol. 1998, 143:1113-1128.
8. Yang X., Tare R.S., Partridge K.A., Roach H.I., Clarke N.M., Howdle S.M., Shakesheff K.M., Oreffo R.O. Induction of human osteoprogenitor chemotaxis, proliferation, differentiation, and bone formation by osteoblast stimulating factor-1/pleiotrophin: osteoconductive biomimetic scaffolds for tissue engineering. J. Bone Miner. Res. 2003, 18:47-57.
9. Tare R.S., Oreffo R.O., Sato K., Rauvala H., Clarke N.M., Roach H.I. Effects of targeted overexpression of pleiotrophin on postnatal bone development. Biochem. Biophys. Res. Commun. 2002, 298:324-332.
10. Perez-Pinera P., Berenson J.R., Deuel T.F. Pleiotrophin, a multifunctional angiogenic factor: mechanisms and pathways in normal and pathological angiogenesis. Curr. Opin. Hematol. 2008, 15:210-214.
11. Mikelis C., Koutsioumpa M., Papadimitriou E. Pleiotrophin as a possible new target for angiogenesis-related diseases and cancer. Recent Pat. Anticancer Drug Discov. 2007, 2:175-186.
12. Bowden E.T., Stoica G.E., Wellstein A. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J. Biol. Chem. 2002, 277:35862-35868.
13. Powers C., Aigner A., Stoica G.E., McDonnell K., Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J. Biol. Chem. 2002, 277:14153-14158.
14. Tomas A., Futter C.E., Eden E.R. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014, 24:26-34.
15. Herbst R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:21-26.
16. Cao C., Huang X., Han Y., Wan Y., Birnbaumer L., Feng G.S., Marshall J., Jiang M., Chu W.M. Galpha(i1) and Galpha(i3) are required for epidermal growth factor-mediated activation of the Akt-mTORC1 pathway. Sci. Signal. 2009, 2:ra17.
17. Cao C., Lu S., Jiang Q., Wang W.J., Song X., Kivlin R., Wallin B., Bagdasarian A., Tamakloe T., Chu W.M., Marshall J., Kouttab N., Xu A., Wan Y. EGFR activation confers protections against UV-induced apoptosis in cultured mouse skin dendritic cells. Cell. Signal. 2008, 20:1830-1838.
18. Maretzky T., Evers A., Zhou W., Swendeman S.L., Wong P.M., Rafii S., Reiss K., Blobel C.P. Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat. Commun. 2011, 2:229.
19. Oganesian A., Yarov-Yarovoy V., Parks W.C., Schwinn D.A. Constitutive coupling of a naturally occurring human alpha1a-adrenergic receptor genetic variant to EGFR transactivation pathway. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:19796-19801.
20. Sur S., Agrawal D.K. Transactivation of EGFR by G protein-coupled receptor in the pathophysiology of intimal hyperplasia. Curr. Vasc. Pharmacol. 2014, [Epub ahead of print].
21. McElroy S.J., Hobbs S., Kallen M., Tejera N., Rosen M.J., Grishin A., Matta P., Schneider C., Upperman J., Ford H., Polk D.B., Weitkamp J.H. Transactivation of EGFR by LPS induces COX-2 expression in enterocytes. PLoS One 2012, 7:e38373.
22. She C., Zhu L.Q., Zhen Y.F., Wang X.D., Dong Q.R. Activation of AMPK protects against hydrogen peroxide-induced osteoblast apoptosis through autophagy induction and NADPH maintenance: new implications for osteonecrosis treatment?. Cell. Signal. 2014, 26:1-8.
23. Talasila K.M., Soentgerath A., Euskirchen P., Rosland G.V., Wang J., Huszthy P.C., Prestegarden L., Skaftnesmo K.O., Sakariassen P.O., Eskilsson E., Stieber D., Keunen O., Brekka N., Moen I., Nigro J.M., Vintermyr O.K., Lund-Johansen M., Niclou S., Mork S.J., Enger P.O., Bjerkvig R., Miletic H. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 2013, 125:683-698.
24. Contessa J.N., Reardon D.B., Todd D., Dent P., Mikkelsen R.B., Valerie K., Bowers G.D., Schmidt-Ullrich R.K. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin. Cancer Res. 1999, 5:405-411.
25. Chan D.W., Chen B.P., Prithivirajsingh S., Kurimasa A., Story M.D., Qin J., Chen D.J. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev. 2002, 16:2333-2338.
26. Kong Y., Bai P.S., Nan K.J., Sun H., Chen N.Z., Qi X.G. Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer. Int. J. Colorectal Dis. 2012, 27:287-298.
27. Zhu X.F., Liu Z.C., Xie B.F., Li Z.M., Feng G.K., Yang D., Zeng Y.X. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 2001, 169:27-32.
28. Zhou H.Y., Ohnuma Y., Takita H., Fujisawa R., Mizuno M., Kuboki Y. Effects of a bone lysine-rich 18kDa protein on osteoblast-like MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 1992, 186:1288-1293.
29. Li G., Cui Y., McIlmurray L., Allen W.E., Wang H. RhBMP-2, rhVEGF(165), rhPTN and thrombin-related peptide, TP508 induce chemotaxis of human osteoblasts and microvascular endothelial cells. J. Orthop. Res. 2005, 23:680-685.
30. Stoica G.E., Kuo A., Aigner A., Sunitha I., Souttou B., Malerczyk C., Caughey D.J., Wen D., Karavanov A., Riegel A.T., Wellstein A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 2001, 276:16772-16779.
31. Souttou B., Raulais D., Vigny M. Pleiotrophin induces angiogenesis: involvement of the phosphoinositide-3 kinase but not the nitric oxide synthase pathways. J. Cell. Physiol. 2001, 187:59-64.
32. Himburg H.A., Muramoto G.G., Daher P., Meadows S.K., Russell J.L., Doan P., Chi J.T., Salter A.B., Lento W.E., Reya T., Chao N.J., Chute J.P. Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat. Med. 2010, 16:475-482.
33. Schacke H., Docke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 2002, 96:23-43.
34. den Uyl D., Bultink I.E., Lems W.F. Advances in glucocorticoid-induced osteoporosis. Curr. Rheumatol. Rep. 2011, 13:233-240.
35. Weinstein R.S. Clinical practice. Glucocorticoid-induced bone disease. N. Engl. J. Med. 2011, 365:62-70.
36. Kerachian M.A., Seguin C., Harvey E.J. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J. Steroid Biochem. Mol. Biol. 2009, 114:121-128.